Format

Send to

Choose Destination
MAbs. 2009 Jan-Feb;1(1):41-8.

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Author information

1
Biocon Limited, Bangalore, India. ramakrishnan.melarkode@biocon.com

Abstract

Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This review focuses on the unique functional characteristics of nimotuzumab. Also, it discusses the safety and efficacy data obtained from the Phase IIb clinical trial conducted in India in SCCHN. Post marketing surveillance data from Cuba for the use of nimotuzumab in pediatric and adult glioma is also discussed. Overall, nimotuzumab has immense therapeutic potential in cancers of epithelial origin.

KEYWORDS:

EGFR; SCCHN; glioma; humanized; monoclonal antibody; nimotuzumab; overall survival

PMID:
20046573
PMCID:
PMC2715181
DOI:
10.4161/mabs.1.1.7509
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center